RSS | Login | Register

DEPODUR

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare DEPODUR to:

Generic Name for DEPODUR

Morphine sulfate 10mg/mL; ext-rel liposomal susp for epidural inj; preservative free.

Legal Classification:

CII

Pharmacological Class for DEPODUR

Opioid.

Manufacturer of DEPODUR

EKR Therapeutics. Inc.

Indications for DEPODUR

Post-op pain after major surgery.

Adult dose for DEPODUR

≥18yrs: Give as a single dose by lumbar epidural inj only, before surgery or after clamping umbilical cord in caesarean section. Individualize. Monitor closely for at least 48 hrs after dosing. Orthopedic surgery (lower extremities): 15mg. Lower abdominal or pelvic surgery: 10–15mg. Caesarean section: 10mg. All: max 20mg.

Children's dosing for DEPODUR

<18 yrs: not recommended.

Contraindications for DEPODUR

Head injury. Increased intracranial pressure. Respiratory depression. Asthma. Upper airway obstruction. Paralytic ileus. Circulatory shock.

Precautions for DEPODUR

Conditions that increase risk of respiratory depression (eg, hypercapnia, obesity, surgery cancellation). Impaired myocardial function. Volume depletion. Biliary tract disease. Acute pancreatitis. Seizure disorders. GI or GU obstruction. Drug abusers. Elderly. Debilitated. Labor & delivery (not for use in vaginal delivery). Pregnancy (Cat.C). Nursing mothers.

Interactions for DEPODUR

During or within 14 days of MAOIs: not recommended. Epidural local anesthetics: allow ≥15 minutes between test dose of lidocaine and epinephrine and DepoDur inj; allow ≥30 minutes between analgesic dose of bupivacaine and Depodur inj. Suspend use of other epidural drugs for at least 48 hrs. Potentiated by other CNS depressants (eg, alcohol, other opiates, general anesthetics, sedatives, antihistamines, phenothiazines). Potentiates neuromuscular blockers.

Adverse Reactions for DEPODUR

CNS and respiratory depression, orthostatic hypotension, urinary retention, GI upset, constipation, paralytic ileus, pruritus, pyrexia, anemia, headache, dizziness, biliary colic, bladder spasm, bradycardia, tachycardia, back pain.

How is DEPODUR supplied?

Single-use vials (1mL, 1.5mL)—5

Related Disease:

Pain, general~narcotics

Exalgo approved for moderate to severe pain

March 02, 2010

The FDA has approved Exalgo (hydromorphone HCl extended-release tablets, from Covidien) for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

Phase 3 study of MoxDuo IR for pain management

February 10, 2010

QRxPharma Limited announced initiation of a second Phase 3 registration trial (Study 009) to evaluate its MoxDuo IR (morphine and oxycodone) product for the management of moderate to severe pain in patients who have undergone total knee replacement surgery.

FDA-approved morphine sulfate oral solution 100mg/5mL available

January 27, 2010

Roxane Laboratories announced that the New Drug Application (NDA) for high concentrate morphine sulfate oral solution 100mg/5mL (20mg/mL) has been approved by the FDA.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

NDA submitted for extended-release tapentadol tablets for chronic pain

December 02, 2009

Johnson & Johnson and its subsidiaries, PriCara and Ortho-McNeil-Janssen, announced that they have submitted a New Drug Application (NDA) to the FDA for tapentadol extended release (ER) tablets for the management of moderate to severe chronic pain in patients ≥18 years of age.